Compare · DVA vs PGNY
DVA vs PGNY
Side-by-side comparison of DaVita Inc. (DVA) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVA and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA is the larger of the two at $11.53B, about 5.4x PGNY ($2.14B).
- Over the past year, DVA is up 49.4% and PGNY is up 25.9% - DVA leads by 23.5 points.
- PGNY has been more active in the news (5 items in the past 4 weeks vs 3 for DVA).
- PGNY has more recent analyst coverage (25 ratings vs 14 for DVA).
- Company
- DaVita Inc.
- Progyny Inc.
- Price
- $187.16-1.04%
- $26.88-2.06%
- Market cap
- $11.53B
- $2.14B
- 1M return
- +2.20%
- -0.43%
- 1Y return
- +49.45%
- +25.94%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 3
- 5
- Recent ratings
- 14
- 25
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest DVA
- DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care
- DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early
- Chief Operating Officer, DKC Maughan David Paul covered exercise/tax liability with 7,501 shares, decreasing direct ownership by 8% to 86,604 units (SEC Form 4) to cover withholding tax
- Alebund Pharmaceuticals Announces 2026 Interim Results
- DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
- Director Hollar Jason M. was granted 278 shares, increasing direct ownership by 4% to 6,883 units (SEC Form 4)
- Director Desoer Barbara J was granted 278 shares (SEC Form 4)
- Director Pullin Dennis W was granted 278 shares, increasing direct ownership by 10% to 2,949 units (SEC Form 4)
- Director Moore Gregory J. was granted 278 shares, increasing direct ownership by 4% to 8,091 units (SEC Form 4)
- Director Yale Phyllis R was granted 278 shares, increasing direct ownership by 3% to 9,803 units (SEC Form 4)
Latest PGNY
- SEC Form 4 filed by Progyny Inc.
- Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting
- Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
- EVP, GC Swartz Allison sold $101,868 worth of shares (3,903 units at $26.10) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 75,816 units (SEC Form 4)
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,009 units (SEC Form 4) to cover taxes
- Amendment: Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $311,858 worth of shares (11,500 units at $27.12) (SEC Form 4)
- Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $321,358 worth of shares (11,500 units at $27.94) (SEC Form 4)
- SEC Form 144 filed by Progyny Inc.
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 806,111 units (SEC Form 4) to satisfy tax liability
- EVP, GC Swartz Allison covered exercise/tax liability with 1,307 shares, decreasing direct ownership by 2% to 79,719 units (SEC Form 4) (withholding tax)